FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the use of enisamium iodide for the treatment of acute respiratory distress syndrome (ARDS), in which the subject orally takes or receives enisamium iodide, the amount of which is selected depending on his condition and ranges from 17 to 180 mg per kg of subject's weight, as well as the use of enisamium iodide for the treatment of acute respiratory distress syndrome (ARDS), in which the subject ingests or receives enisamium iodide in an amount of 52 mg per kg, three times a day, until the subject achieves a decrease in leukocyte infiltration to 69.4% or less, until the absolute number of neurophiles decreases to 66.3% or less, until the concentration of IL-6 decreases to 74.7% or less, and until the concentration of IL-10 decreases to 33.3% or less.
EFFECT: invention makes it possible to treat ARDS, increase the survival of patients by preventing their connection to oxygen, reduce the time spent by patients connected to oxygen, reduce the total dose of surfactant during therapy, reduce the risk of side effects of ARDS therapy, complications and mortality in patients who have undergone ARDS, due to use of enisamium iodide.
14 cl, 11 tbl, 6 dwg
